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Introduction
Heme oxygenase (HO) catalyses the break-down of haem into 
carbon monoxide (CO), free iron, and biliverdin that is rapidly con-
verted into bilirubin by biliverdin reductase. To date, two functional
isoforms of HO have been described in human beings [1]. HO-1 is
inducible by diverse stimuli, including mediators of oxidative
stress and inflammation, whereas HO-2 is thought to be mainly
constitutively expressed [2]. HO-1 is important as part of the
defense mechanism against oxidative stress and inflammation.
Moreover, because HO-1 is largely responsible for iron recycling
by liberating iron mostly from haem catabolism after phagocyto-
sis of senescent erythrocytes by tissue macrophages, its contribu-
tion to iron homeostasis has been postulated.
Recently, hepcidin, a peptide mostly produced in hepatocytes
that is encoded by the HAMP gene in human beings, has been
demonstrated as a key regulator of body iron homeostasis [3].
This peptide inhibits iron efflux from enterocytes and
macrophages by inactivating the major cellular iron exporter, fer-
roportin [4, 5]. Hepcidin action may explain several genetic causes
of iron overload syndrome [6]. Additionally, hepcidin levels are
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Heme oxygenase-1 (HO-1) contribution to iron homeostasis has been postulated, because it facilitates iron recycling by liberating iron
mostly from heme catabolism. This enzyme also appears to be responsible for the resolution of inflammatory conditions. In a patient
with HO-1 deficiency, inflammation and dysregulation of body iron homeostasis, including anemia and liver and kidney hemosiderosis,
are evidenced. Here we postulated that HO-1 is critical in the regulation of ferroportin, the major cellular iron exporter, and hepcidin, the
key regulator of iron homeostasis central in the pathogenesis of anemia of inflammation. Our current experiments in human THP-1 mono-
cytic cells indicate a HO-1-induced iron-mediated surface-ferroportin expression, consistent with the role of HO-1 in iron recycling.
Surprisingly, we observed low hepcidin levels in the HO-1-deficient patient, despite the presence of inflammation and hemosiderosis,
both inducers of hepcidin. Instead, we observed highly increased soluble transferrin receptor levels. This suggests that the decreased
hepcidin levels in HO-1 deficiency reflect the increased need for iron in the bone marrow due to the anaemia. Using human hepatoma
cells, we demonstrate that HO-activity did not have a direct modulating effect on expression of HAMP, the gene that encodes for 
hepcidin. Therefore, we argue that the decreased iron recycling may, in part, have contributed to the low hepcidin levels. These findings
indicate that dysregulation of iron homeostasis in HO-1 deficiency is the result of both defective iron recycling and erythroid activity-
associated inhibition of hepcidin expression. This study therefore shows a crucial role for HO-1 in maintaining body iron balance.
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elevated during inflammation [3]. This acts on the one hand as a
crucial causative factor in pathogenesis of anaemia of inflamma-
tion, by retention of heme-derived iron in the iron storage sites,
thereby withholding it from the erythroid compartment [7–9] On
the other hand, hepcidin suppression is observed in anemias, nec-
essary to increase iron supply needed for the accelerated erythro-
poietic activity [10].
It has been reported that HO-1 deficiency in human exhibits
both signs of inflammation and dysregulation of body iron home-
ostasis, such as iron accumulation in the kidneys and the liver
(Table 1) [11, 12]. Similarly, Ho-1 knock-out mice (Ho-1 KO mice)
developed severe inflammation and anemia associated with low
transferrin iron, and also hepatic and renal iron accumulation
(Table 1) [13]. Therefore, it has been proposed that HO-1 facili-
tates iron efflux from hepatic and renal cells. Another in vitro study
suggested a function for HO-1 in regulating cellular iron by induc-
ing iron efflux [14]. Indeed, in 2000, the same group proposed the
presence of an iron ATPase transporter that in association with
HO-1 acts as an iron exporter [15].
In the present study, we hypothesized that dysregulation of
iron homeostasis present in HO-1 deficiency was mediated by
modulation of hepcidin expression. We therefore investigated HO-1
cross-talk with hepcidin and ferroportin, in order to delineate the
mechanistic basis of body iron regulation, and furthermore to help
explain the dysregulation of iron homeostasis in HO-1 deficiency.
Direct links between HO-1 and HAMP expression were assessed in
human hepatoma cell lines, whereas effects of HO-1 on ferroportin
expression were examined in human THP-1 monocytic cells.
Furthermore, we evaluated these results with the measured levels
of serum hepcidin, inflammatory markers, hematological meas-
urements and iron parameters, in blood or serum samples of the
HO-1-deficient patient.
Materials, methods and patient
Cell culture
Both human hepatoma cell lines, HepG2 and Hep3B, were cultured in a
humidified 37C incubator with 5% CO2 using PC-1 medium (Cambrex,
Walkersville, MD, USA). Human THP-1 monocytic cells were cultured in
RPMI1640 (Gibco, Breda, The Netherlands) supplemented with 2 mmol/l
L-glutamine and 10% heat-inactivated foetal calf serum (Gibco).
Viability test
Cell viability after various treatments was monitored using a standard try-
pan blue exclusion test. In all experiments, both hepatoma and THP-1 cells
were 95% viable after indicated treatments.
Quantitative polymerase chain reaction (Q-PCR)
Confluent hepatoma cells were treated for 6 hrs with different agents,
including tin mesoporphyrin (SnMP, Frontier Scientific, UT, USA), cobalt
protophorphyrin (CoPP, Frontier Scientific), hemin (Frontier Scientific) as
the source of heme, and interleukin-6 (IL-6, R&D systems, Minneapolis,
MN, USA). Two mmol/l stock solutions of SnMP, CoPP and hemin were
freshly prepared as previously described [16]. Isolation of total RNA and
subsequent cDNA synthesis were performed [17], followed by Q-PCR of the
following human cDNAs: HAMP, HO-1 and, for normalization of expression,
the housekeeping gene hypoxanthine phosphoribosyltransferase (HPRT).
Q-PCR was performed in a 25-l total reaction, using TaqMan Universal
Master Mix (PE Applied Biosystems, Foster City, CA, USA). TaqMan enzyme
was activated for 10 min. at 95C before 40 two-step cycles were performed
(30 sec., 95C; 1 min., 60C) in a ABI Prism 7700 (PE Applied Biosystems).
All primers and probes were purchased from PE Applied Biosystems
(HAMP, assay no. Hs00221783_m1; HO-1, assay no. Hs00157965_m1;
HPRT, assay no. 4310890E). Relative expression of the specific target gene
in comparison to the reference housekeeping gene was calculated based on
a mathematical model as previously described [18].
Flow cytometry
After treatment with HO-1 inducers, HO-activity inhibitor, Fe(III)ammonium -
citrate (Sigma, MO, USA) or deferoxamine (DF, Novartis, The Netherlands),
THP-1 cells were fixed using phosphate-buffered saline (PBS, Gibco)
containing 4% paraformaldehyde (Sigma) for 5 min. Blocking of Fc 
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HO-1-deficient mice
[13]
HO-1-deficient
patient [11, 12]
Anemia  
Fragmentation ? 
RBC morphology
Microcytic, 
anisocytosis
Microcytic, 
anisocytosis
Blood transfusion – Regularly
Leukocytosis  
Ferritin Elevated Elevated
Serum iron Low Low normal
Transferrin saturation Low Low
Hemosiderosis
Hepatic parenchymal
and Kupffer cells,
renal proximal tubules
Hepatic parenchymal
and Kupffer cells,
renal proximal tubules
Hepatomegaly  
Splenomegaly Enlarged spleen Asplenia
Glomerulonephritis  
Chronic inflammation Progressive
Steady, receiving 
anti-inflammatory
medications
Table 1 Comparison of some conditions between HO-1-deficient mice
and man
HO-1, heme oxygenase-1; RBC, red blood cells.
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receptors was carried out by incubating the cells in PBS containing 20%
normal human serum (NHS) for 30 min. at 4C. Incubation with 1:25 ferro-
portin antibody (a generous gift from Dr. A.T. Mckie and Dr. G.O. Latunde-
dada, King’s College, London, UK), 1:50 HO-1 antibody (SPA895, Stressgen
Sanbio, Uden, The Netherlands) or 5 g/ml rabbit IgG isotype control
(Rockland Immuno chemicals, Gilbertsville, PA, USA) was done for 3 hrs in
PBS containing 10% NHS at 4C. After washing, labelling with 5 g/ml Alexa-
fluor-488-labelled secondary antibody (Molecular Probes, Eugene, OR, USA)
was per formed for 30 min. in PBS containing 10% NHS at 4C. For HO-1
labelling, 0.05% tween-20 (Sigma) was included during incubation for perme-
abilization. Each flow cytometric measurement was performed using a Becton
Dickinson FACScan (Oxnard, CA, USA) and 1  104 cells were analysed.
HO-activity assay
After treatment as described in the previous section, 1  105 cells were
resuspended in 89.9 l 0.1 mol/l phosphate buffer, 2 mmol/l MgCl2 (pH 7.4)
and subsequently lysed by three freeze-thaw cycles. HO-activity was meas-
ured as described previously [55]. In brief: to the cell lysate, 10.1 l master
mix was added that consisted of 2.5 l 80 mmol/l glucose-6-phosphate,
0.1 l 0.5 U/l glucose-6-phosphate dehydrogenase in 5 mmol/l glycine
(both Sigma-Aldrich), 5 l 32 mmol/l NADPH tetrasodium salt (Roche,
Basel, Switzerland) and 2.5 l 2 mmol/l hemin. The samples were incu-
bated for 60 min. at 37C in the dark. Next, 100 l methanol was added
and the samples were centrifuged at 13,000  g. A 50-l aliquot of this
sample was run on a HPLC (Spectrasystem SCM400, Spectra-Physics
Analytical, Minneapolis, MN, USA) equipped with a 5 m discovery C18
column and a discovery C18 super guard cartridge 5 m particle size pre-
column (both Sigma-Aldrich). Separation was done by performing a gradi-
ent of 80% solvent A (40% 100 mmol/l ammoniumacetate pH 5.5, 5%
methoxy ethanol and 50% methanol (all Sigma-Aldrich) to 20% solvent B
(5% methoxy ethanol and 95% methanol) over a 20-min. time interval at a
flow rate of 1 ml/min. Biliverdin and bilirubin were detected at a wavelength
of 377 and 450 nm, respectively. Standards of biliverdin and bilirubin (both
Frontier Scientific) were also run in order to quantify the amount of
biliverdin/bilirubin found in the samples.
Fluorescence microscopy
After treatment, THP-1 cells were spun at 500  g for 10 min. in 100 l
PBS onto a slide, air dried and fixed in acetone. Incubation with 1:25 fer-
roportin antibody was done for 1 hr in PBS containing 10% NHS at room
temperature. After careful washing, labelling with 5 g/ml Alexa-fluor-
488-labelled secondary antibody was performed for 30 min. in PBS 
containing 10% NHS at room temperature. The slide was covered with
fluorescence-preserving mounting media (Invitrogen Lifesciences,
Breda, The Netherlands) and a glass cover slip, and further visualized
using a Leica fluorescence microscope (Leica Microsystems, GmbH,
Heidelberg, Germany).
Calcein assay for measurement of intracellular
labile iron
A calcein assay was used to monitor intracellular labile iron accumulation
as described elsewhere [19, 20]. In this assay, after treatment and washing,
hepatoma or THP-1 cells were incubated with 0.1 mol/l calcein-AM
(Molecular Probes, OR, USA) for 30 min. at 37C, in the presence of 
5 mol/l PSC-833, a P-glycoprotein inhibitor (Novartis), to avoid efflux of
calcein-AM [21]. The cells were then washed twice to remove the remain-
ing extracellular calcein-AM. The fluorescence signals of calcein (excitation
485 nm, emission 530 nm) were read in the Cytofluor II microplate reader
(Perspective Biosystems, Framingham, MA, USA). Fractional decreases in
fluorescence intensity correlates with intracellular labile iron level [19, 20].
Fe(III)ammoniumcitrate was used as a positive control to illustrate sensi-
tivity of the assay.
HO-1-deficient patient and laboratory 
measurements
A patient with no functional HO-1 expression because of a two-nucleotide
deletion within exon3 and a complete loss of exon2 of the HO-1 genes has
been described previously [11, 12]. Informed consent was obtained and the
study was approved by the Ethics Committee of Kanazawa University [11,
12]. The sera of the patient taken at two different time points exhibited low
transferrin saturation, but elevated levels of ferritin and heme (Table 2).
Several laboratory parameters of the sera, as shown in Table 2, were meas-
ured in previous studies [11, 12], and remeasured in the present study. The
two samples were taken 5 months apart when the patient was 6 years old.
The boy died several months after the last blood sample was taken. Both
samples were stored at 80C. Remeasurement of laboratory parameters
of the stored samples in the present study was carried out using routine lab-
oratory methods [8] (Department of Clinical Chemistry, Radboud University
Nijmegen Medical Centre, The Netherlands). Serum hepcidin was measured
using surface-enhanced laser desorption/ionization time-of-flight mass
spectrometry (SELDI-TOF-MS) as described elsewhere [22]. As reference
values, hepcidin levels were measured in sera of healthy volunteers that had
been stored at 80C for a similar period of time as the patient sera, i.e. 8
years. Soluble transferrin receptor (sTfR) was measured using the Dade
Behring sTfR assay (Marburg, Germany). Ferric iron deposition has been
reported in the renal and hepatic tissues, following a standard Prussian-blue
staining method (Table 1) [11, 12]. The patient also suffered from persistent
haemolytic anaemia, characterized by erythrocyte fragmentation and elevated
LDH and aspartate aminotransferase (AST) levels in the presence of only
slightly elevated alanine aminotransferase (ALT) levels (Table 2). The patient
was asplenic and required regular transfusions of erythrocytes (Table 1).
Statistical analysis
Results are expressed as means  standard errors of the means (S.E.).
Differences in quantitative measures were tested for significance using
one-way ANOVA. All statistics were performed using the GraphPad Prism 4
statistical program (San Diego, CA, USA).
Results
HO-activity increases intracellular labile iron 
levels in THP-1 cells
Previous studies [13–15] have suggested a role for HO-1 in maintain-
ing intracellular iron levels by promoting iron efflux. This may imply a
central role for HO-1 in maintaining intracellular iron homeostasis.
© 2008 The Authors
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Here, we analysed intracellular labile iron pool in THP-1 cells after
induction or inhibition of HO-activity, utilizing a calcein assay.
In THP-1 cells, 24 hrs treatment with Fe(III)ammonium -
citrate quenched the calcein signal (Fig. 1). The quenched 
signal was returned to basal levels when DF, the specific iron
chelator, was added. This result indicates that iron-rich conditions
promote intracellular labile iron accumulation. In these cells, 24-hr
induction of HO-1 by heme also promoted calcein quenching
© 2008 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
First blood sampling Second blood sampling Reference values
Hematological parameters
WBC (/l) 27,300 19,300 3300–8800
RBC (104/l) 221 195 430–550
Hb (g/dl) 7.1 5.6 13.5–17.0
Hct (%) 19.1 15.3 39.7–51.0
MCV (fL) 86.4 78.5 83–102
MCHC (%) 37.2 36.6 32–36
Iron parameters
Ferritin (ng/ml) 965 (2146) 595 (2065) 6–280 (26–360)
TIBC (mol/l) 98 (94) 76 (82) 48–71 (45–75)
Serum iron (mol/l) 7.5 (12) 12 (10) 8.9–30 (7–25)
Transferrin saturation (%) (12.8) (12.2) (17–42)
Transferrin (mg/dl) 424 n.d. 214–390
Serum heme (mol/l)  400  400 	1
Inflammatory parameters and organ injury
CRP (mg/l) 12.4 (17) 6.1(9) 	0.5 (	10)
IL-6 (pg/ml) (20) (28) (	5)
Creatinine (mol/l) (97) (74) (44–71)
ALT (IU/l) 40 (49) 40 (54) 2–39 (10–25)
AST (IU/l) 408 369 15–50
LDH (IU/l) 18,010 19,620 196–355
TP (g/dl) 10.1 9.1 6.6–8.1
Haptoglobin (mg/dl) 878 n.d. 30–252
Serum hepcidin (MInt/l) (	0.1) (<0.1) (0.6–9.9)‡, (1.02–6.26)*
sTfR (mg/l) (19.4) (34.1) (0.76 – 1.76)
Table 2 Hematological, iron and inflammatory parameters of the HO-1-deficient patient
Laboratory parameters were measured in previous studies [11, 12] and the present study. The presented values measured in the present study are
in brackets. Reference values were based on the laboratory standards for males age 4–9 years old (Department of Clinical Chemistry, Radboud
University Nijmegen Medical Centre, The Netherlands) or previous studies [11, 12]. ‡Based on a range of values obtained from 20 fresh sera of
normal controls [22]. *Based on values obtained from 6- to 8-year stored sera of normal controls (Mint/l). HO-1, heme oxygenase-1; WBC, white
blood cells; RBC, red blood cells; Hb, haemoglobin; Hct, hematocrit; MCV, mean corpuscular volume; MCHC, mean corpuscular haemoglobin con-
centration; TIBC, total iron-binding capacity; CRP, C-reactive protein; IL-6, interleukin-6; TNF-
, tumour necrosis factor-
; ALT, alanine aminotrans-
ferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; TP, total protein; sTfR, soluble transferrin receptor; IU, international unit;
Mint/l, Mega intensity/litre; *as previously described [22]; n.d., not determined.
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(Fig. 1). This effect could be counteracted using SnMP, the spe-
cific HO-activity inhibitor. Thus, this result indicates that iron
derived from intracellular heme degradation by HO-activity con-
tributes to the increased levels of intracellular labile iron.
However, the specific HO-1 inducer CoPP [23] did not promote
accumulation of intracellular labile iron in THP-1 cells. This is
likely due to a shortage of heme as the substrate of HO in the
cells after 24 hrs of CoPP incubation [24, 25]. IL-6 treatment
moreover did not affect the levels of intracellular labile iron.
Taken together, our data demonstrate that increased HO-activity,
in the presence of sufficient heme substrate, promotes accumu-
lation of intracellular labile iron. Thus although HO-1 promotes
cellular iron efflux [13–15], the level of intracellular labile iron
is still increased.
The calcein assay was carried out in the presence or absence
of PSC-833, an inhibitor of the calcein-AM transporter, P-glyco-
protein, to avoid efflux of calcein-AM [21]. However, no differ-
ences in calcein quenching levels were observed when the results
were compared with the assays performed without PSC-833 (data
not shown).
Ferroportin induction by intracellular labile iron
in human macrophage/monocyte-like cells
To examine whether HO-1 could directly regulate the iron exporter
ferroportin, expression of ferroportin in THP-1 cells treated with
HO-activity modifying agents was analysed. This study was also
aimed to examine direct involvement of HO-1 in cellular iron efflux
as has been postulated [13–15].
Increased HO-1 synthesis in THP-1 by heme (Fig. 2A and B)
correlated with elevated expression of surface ferroportin 
(Fig. 3A–C). Here, an incubation period of 24 hrs was chosen to allow
stable surface expression of ferroportin on THP-1 cells. Addition
of the specific HO-activity inhibitor SnMP [16, 26] did not affect
heme-induced HO-1 expression (Fig. 2B), however, it counteracted
© 2008 The Authors
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Fig. 1 Detection of intracellular labile iron in THP-1 cells. Calcein assay
was performed in THP-1 cells after indicated treatments for 24 hrs.
Quenching of calcein fluorescence indicates increased intracellular labile
iron. Each measurement is the mean value  S.E., n 3, *lower than the
corresponding controls (P 	 0.05).
Fig. 2 Detection of HO-1 protein expression in THP-1 cells. HO-1 expres-
sion was analysed by FACS analysis in THP-1 cells after indicated treat-
ments for 24 hrs. Prior to FACS analysis, cells were permeabilized and
stained with anti-HO-1 IgG antibody, followed by the labelled secondary
antibody. (A) The histogram illustrates several read-outs of FACS analysis,
y-axis  events or cell numbers, x-axis  protein expression based on
fluorescence intensity, a.u.  arbitrary units. IgG control  cells stained
with IgG isotype control. (B) shows HO-1 expression levels in THP-1 cells
after indicated treatments. Each FACS measurement is the mean value 
S.E., n  3–4, *lower than the corresponding controls (P 	 0.05).
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Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 3 Detection of ferroportin protein expression on THP-1
cells. Ferroportin expression was analysed by FACS analysis on
THP-1 cells after indicated treatments for 24 hrs. Prior to FACS
analysis, cells were fluorescently stained with anti-ferroportin
antibody, followed by the labelled secondary antibody. (A) The
histogram illustrates several read-outs of FACS analysis, 
y-axis  events or cell numbers, x-axis  protein expression
based on fluorescence intensity, a.u.  arbitrary units. IgG
control  cells stained with IgG isotype control. (B) shows 
ferroportin expression levels in THP-1 cells after indicated
treatments. Each FACS measurement is the mean value  S.E.,
n 3–4, *lower than the corresponding controls (P	 0.05). (C)
After 24 hrs of specified treatments, THP-1 cells were stained
using anti-ferroportin antibody, followed by the labelled sec-
ondary antibody. Expression of surface ferroportin in green
was visualized using fluorescence microscopy. Enhanced
green colour indicates increased ferroportin expression. The
images are representative of two independent experiments.
J. Cell. Mol. Med. Vol 13, No 9B, 2009
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HO-induced ferroportin expression (Fig. 3B), confirming that HO-
activity modulates surface ferroportin expression.
THP-1 incubation with CoPP for 24 hrs, however, although
promoting HO-1 expression (Fig. 2B), did not stimulate ferroportin
expression (Fig. 3B). This is consistent with the absence of intra-
cellular iron accumulation after CoPP stimulation (Fig. 1). Thus,
increased intracellular labile iron levels are necessary for induction
of ferroportin expression. This was supported by our observation
that iron chelator DF was able to counteract both heme-induced
and iron-induced ferroportin expression (Fig. 3B). DF appeared to
also counteract the increased levels of intracellular labile iron (Fig. 1).
In addition, we observed that ferroportin expression was
induced by IL-6 (Fig. 3B). Such induction of ferroportin by a proin-
flammatory cytokine has been previously reported [27]. This
induction however is likely independent of HO-activity because
SnMP did not counteract the effect of IL-6.
Taken together, the results indicate that surface ferroportin
expression is induced by intracellular labile iron. These data there-
fore suggest that the previously described HO-1-induced iron
efflux [13–15] is likely mediated by a heme-derived iron-induced
ferroportin expression.
Despite chronic inflammation and tissue iron
loading in the HO-1-deficient patient there is lack
of hepcidin synthesis
Because HO-1 deficiency results in tissue iron loading (Table 1)
and chronic inflammation shown by enhanced levels of IL-6, CRP
and haptoglobin (Table 2), we questioned whether HO-1 modu-
lates the synthesis of liver hepcidin. We measured hepcidin levels
using SELDI-TOF-MS in serum samples of the HO-1-deficient
patient and from six healthy volunteers that were stored in 80C
for a similar time period and thus served as reference values
(Table 2). Hepcidin levels from two serum samples of the patient
from different periods of collection were measured to monitor the
consistency of the values. Because of the presence of pathological
chronic inflammation and tissue iron loading conditions, together
with low transferrin saturation, but highly elevated ferritin levels
(Table 2), hepcidin levels in the sera were expected to be
increased. However, on the contrary, we found that hepcidin lev-
els, in the two serum samples of the HO-1-deficient patient were
very low (both values were 	0.1 Mint/l, whereas normal range of
fresh sera  0.6–9.9 Mint/l [22], and normal range of stored sera
 1.02–6.26 Mint/l, Table 2). These measured low levels of hep-
cidin in the stored patient sera are likely reflecting actual levels
because (1) based on our methodology of hepcidin measurement,
serum hepcidin preserves its stability even after several freeze-
thaw cycles during storage [22], (2) similarly, stored samples
from healthy volunteers showed significantly higher levels of hep-
cidin, (3) additionally, values of both iron and serum parameters
that had been measured previously in the fresh samples of the HO-1
patient [11] were similar as measured in the present study (Table 2),
indicating that the stored serum samples were well preserved, and
(4) moreover, both patient serum samples collected at different
sampling points consistently showed low hepcidin levels.
Together, these observations provide a strong argument that the
HO-1 deficiency led to decreased hepcidin synthesis. The ferritin
values however were higher in the current measurements com-
pared to the previous ones [11], which is likely due to different
equipments used in the two laboratories, as well as to the world-
wide variability and a lack of standardization in ferritin assays.
Thus despite increased iron stores and inflammation, the patient
has very low hepcidin levels.
HO-1-activity was inducible in human hepatoma
cells, and promoted intracellular labile iron 
accumulation
Because HO-1 deficiency exhibited hepcidin suppression, we
questioned whether HO-1 could directly modulate HAMP expres-
sion in liver cells. We first tested whether HO-1-activity could be
induced in human hepatoma cells, and promote intracellular labile
iron accumulation.
In HepG2 cells, treatment with 10 M heme for 6 hrs promoted
substantial induction of HO-activity when compared to basal activity
levels, whereas exposure to 10 M SnMP, completely abrogated
HO-activity in these cells (data not shown). This confirms that 
in our in vitro systems, heme activated while SnMP inhibited HO-
activity, as previously reported [16, 26].
In HepG2 and Hep3B cells (Fig. 4A), after 6 hrs, induction of
HO-1 with heme or CoPP quenched the calcein signal, indicating
accumulation of intracellular labile iron. The quenched calcein sig-
nal could be returned to basal levels when SnMP was added,
demonstrating that HO-activity in human hepatoma cell lines also
promotes intracellular iron accumulation. Cells treated with either
increasing concentrations of heme (Fig. 4B) or Fe(III)ammonium -
citrate (Fig. 4C) also showed increased levels of intracellular labile
iron. In agreement with previous observations using THP-1 cells,
our data indicate that HO-1-activity promotes labile iron accumu-
lation in the cells.
HO-1 does not modulate HAMP expression in
human hepatoma cells
We next examined whether HO-1 could directly down-modulate
HAMP expression in liver cells. To this end, we incubated HepG2
and Hep3B cells with HO-1 modulating agents, and measured
HAMP transcript levels.
Incubation with the specific HO-activity inhibitor [16, 26], SnMP,
for 6 hrs modulated neither the amount of HO-1 nor HAMP tran-
scripts (Table 3). Likewise, prolonged incubation (i.e. 24 and 48 hrs,
data not shown) did not affect transcript levels of both genes.
CoPP increased HO-1 transcripts in both cell lines, however
HAMP expression was not changed. Moreover, inhibition of HO-
activity using SnMP in the presence of CoPP did not alter HAMP
© 2008 The Authors
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transcription (Table 3). These results indicate no direct modula-
tory effects of HO-1 levels and HO-activity on HAMP expression.
In the presence of IL-6, both HO-1 and HAMP transcripts were
up-regulated (Table 3). Because IL-6 could regulate both genes
directly at transcriptional level [28–30], the observed up-regula-
tion is likely independent from each other. Furthermore, when HO-
activity was inhibited, IL-6-induced HAMP expression was not
affected. This further confirms the absence of direct modulatory
effects of HO-activity on HAMP expression in hepatoma cells.
In contrast, it was observed that upon HO-1 induction by
heme, HAMP was slightly decreased, although this was not sig-
nificant (Table 3). This effect may be attributed to increased levels
of intracellular labile iron [31, 32] from heme degradation by
HO-1 in hepatoma cells (Fig. 4). Similarly, after iron treatment
(Table 3), although HO-1 is up-regulated, HAMP expression was
not changed. In this iron-enriched condition, when HO-activity
was inhibited by co-exposure to SnMP, HAMP expression
stayed low (Table 3). On the other hand, in the presence of both
heme and SnMP, the unmetabolized heme up-regulated HO-1,
and to a lesser extent, enhanced HAMP expression. The latter
observation however may not be relevant in vivo, because this
requires complete inhibition of HO-activity, whereas in vivo,
other pathways of heme degradation including the HO-2 path-
way [2] are present. Taken together, these cellular data show
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Fig. 4 Detection of intracellular labile iron in human hepatoma cells, HepG2 and Hep3B. (A–C) show relative levels of intracellular iron after 6 hrs of
indicated treatments. Quenching of calcein fluorescence indicates increased intracellular labile iron in the cells. Each measurement is the mean value 
S.E., n  3–4, *lower than the corresponding controls (P 	 0.05).
Treatment Relative HAMP expression Relative HO-1 expression
Hep3B HepG2 Hep3B HepG2
Control 1 1 1 1
10 mol/l SnMP 1.2  0.2 1.1  0.2 1.7  0.2 1.3  0.3
20 mol/l SnMP 0.9  0.3 1.8  0.5 1.6  0.8 1.9  0.2
10 mol/l CoPP 0.8  0.2 1.2  0.4 65  24* 62  15*
10 mol/l CoPP  10 mol/l SnMP 0.7  0.2 0.8  0.3 62  13* 74  14*
10 ng/ml IL-6 72  21* 22  7.2* 3.4  0.9 5.4  2.1*
10 ng/ml IL-6  10 mol/l SnMP 65  11* 20.4  5.9* 2.2  1.1 5.2  1.1*
10 mol/l heme 0.4  0.2 0.6  0.3 75  12 * 69  23*
10 mol/l heme  10 mol/l SnMP 6.8  2.1* 6.4  4.1 89  22 * 87  14*
10 mol/l Fe(III)amn.cit. 0.8  0.2 n.d. 14.3  1.5* n.d.
10 mol/l Fe(III)amn.cit.  10 mol/l SnMP 1.6  0.4 n.d. 18.6  3.9* n.d.
Table 3 Transcript levels of HAMP and HO-1 in human hepatoma cells after 6 hrs of specified treatments
HO-1, heme oxygenase-1; SnMP, tin mesoporphyrin; CoPP, cobalt protoporphyrin; IL-6, interleukin-6; Fe(III)amn.cit., Fe(III)ammoniumcitrate. Each
measurement is the mean value  S.E., n  3–4, n.d.  not determined,
*Higher than the corresponding controls (P 	 0.05).
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lack of direct modulatory effects of HO-1 on cellular HAMP
expression in vitro.
Anemia in HO-1 deficiency increases 
erythropoietic activity that attenuates hepcidin
synthesis
Because no direct modulation by HO-activity on HAMP expression
was found in vitro, we questioned why hepcidin levels were so low
despite the presence of chronic inflammation and iron accumula-
tion in the HO-1-deficient patient. Because hepcidin expression
can be down-regulated when an elevated erythropoietic drive is
present [10, 33–35], we postulated that this hepcidin suppression
in the HO-1-deficient patient could be the result of increased ery-
thropoietic activity. To verify this, we measured sTfR, a measure of
erythropoietic activity in the bone marrow [36], in the patient sera.
sTfR levels were exceptionally high (19.4 mg/l from the first taken
serum, and 34.1 mg/l from the second drawn serum, reference
values are 0.76–1.76 mg/l) (Table 2). Increased sTfR levels in the
two samples correlated well with decreased Hb levels, erythrocyte
counts and the increased levels of the hemolytic indices AST and
LDH (Table 2).
Discussion
HO-1 is not only vital for iron recycling by liberating iron from
heme and haemoproteins, it is also crucial for the resolution of
oxidative stress and inflammatory conditions [1, 16, 37, 38]. HO-1
deficiency in vivo resulted in anaemia and hepatic and renal
haemosiderosis [11, 16, 38–41]. The deficiency also promotes
severe chronic inflammation [11, 16, 38–41] as shown by
increased CRP, IL-6 and haptoglobin (Table 2). The serum levels
of haptoglobin are usually very low during intravascular haemolysis,
because haptoglobin binds to the free haemoglobin in the circula-
tion which then will be rapidly cleared out by the reticuloendothe-
lial system. In the HO-1 deficiency, markedly elevated haptoglobin
levels are likely to be originated from the more dominant effect of
inflammation than the observed haemolysis. Moreover, it was
observed that the Kupffer cells of the HO-1-deficient patient had
diminished haptoglobin-receptor levels (A. Yachie, unpublished
observation). Finally, due to the asplenic condition, the clearance
of haptoglobin-haemoglobin complex may also be prolonged in
this patient. The circulating toxic unmetabolized heme may further
enhance oxidant-mediated cellular damage [42, 43], inflammation
[16, 37, 38] and haemolysis [11]. Similarly to the HO-1-deficient
patient, accelerated hepatic iron loading has also been docu-
mented when Ho-1 KO mice were challenged with stress stimuli
[39–41]. Together these data suggest that HO-1 is crucial for both
cell protection against oxidative and inflammatory injury as well as
for maintaining iron homeostasis.
Our experiments were aimed at resolving whether distortion of
iron homeostasis in HO-1 deficiency is mediated by hepcidin. As
demonstrated in hepatoma cells, direct modulation of HO-1
expression levels and HO-activity did not affect hepcidin expres-
sion, suggesting that HO-1 is not a direct upstream regulator of
hepcidin expression.
To our surprise we observed very low serum hepcidin levels in
the HO-1-deficient patient despite the presence of chronic inflam-
mation and iron accumulation, both strong inducers of hepcidin.
However, the observed hepcidin suppression is likely crucial as it
provides bioavailable iron for erythropoiesis to compensate for the
hemolysis and anemia (Fig. 5). Indeed, extremely high sTfR levels
were measured, confirming the presence of increased erythropoi-
etic activity. In agreement with our findings, in mice models of
hemolysis, iron loading and inflammation are sustained, whereas
production of hepcidin is suppressed [44]. This is further corrob-
orated in a rat model of hemolysis [45]. The patient’s decreased
serum hepcidin levels are thus likely to be the result of increased
erythroid expansion that, by analogy with growth differentation
factor-15 exclusively present in -thalassaemia [35] through the
systemic release of a thus far unknown factor, down-regulates
hepatocyte hepcidin production. In addition, a down-regulatory
effect of the anemia-associated tissue hypoxia on liver hepcidin
expression may also contribute to the low hepcidin levels [46, 47].
We further investigated whether HO-1 could directly modulate
ferroportin expression. Surface expression of ferroportin [5] was
increased in THP-1 monocytic cells when HO-1 expression was
induced in the presence of sufficient heme substrate. When HO-
activity was inhibited by SnMP, HO-mediated ferroportin expres-
sion was abrogated. This induction of ferroportin by HO-activity
may explain previously-reported HO-1-induced iron efflux [14,
15]. However, HO-mediated ferroportin expression appeared to be
regulated by the HO-derived effector molecule, iron, because
deferoxamine, an iron chelator, could inhibit the HO-activity-
induced ferroportin. Thus, these findings indicate that iron reuti-
lization is affected in HO-1 deficiency [13], due to failure in heme
catabolism, and not to the absence of HO-1 as a regulator of cellular
iron homeostasis [14] nor as being part of a putative iron exporter
[15] as previously suggested. The HO-derived iron-induced ferro-
portin protein expression is possibly regulated at the transcrip-
tional level via its iron responsive element [48].
Under normal circumstances, HO-activity promotes heme
catabolism and thereby facilitates iron recycling back to the
plasma as iron-bound transferrin to exert its regulatory function
via the hepatocyte transferrin receptors [49]. The decreased iron
recycling, because of HO-1 deficiency, and subsequently, lower
serum iron-transferrin levels may, in part, have contributed to the
observed low hepcidin levels. Both decreased recycling of iron
from heme and fast consumption of bioavailable iron from the cir-
culation by the bone marrow for the increased erythropoiesis
activity may therefore have promoted low levels of transferrin sat-
uration in this patient (Fig. 5).
During hemolysis, clearance of plasma heme and heme-contain-
ing proteins is carried out by the proximal tubular cells of the kidneys.
This event is deleterious for the kidneys as exemplified by the extent
of iron deposition in the proximal tubuli [11] and the tubular atrophia
[12] of the HO-1-deficient patient. Iron also accumulated in the liver,
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because this organ is capable of effectively incorporating the vast-
majority of plasma heme [50]. The loosely bound Fe(III) accumula-
tion detected in the liver and the kidneys of this patient by Prussian
blue (Tables 1 and 3) could be originated from heme that was
degraded to Fe(III) by other pathways than HO-1, including the HO-2
pathway, which is constitutively present at a low level [2] and the
non-CO-forming pathways [50], or from the oxidized free heme [51].
Besides having defective macrophage iron recycling, HO-1
deficiency also exhibited hepatocyte iron loading in the liver (Table 1)
[11, 12]. Similarly, Ho-1 KO mice show both hepatocyte and
Kupffer iron overload [13], whereas stress stimuli further induce
iron loading exclusively in hepatocytes [39]. In this study, we have
observed low hepcidin levels in the patient with HO-1 deficiency,
which are similar to that of patients with juvenile forms of heredi-
tary hemochromatosis [52–54]. These low concentrations of hep-
cidin may help explain the presence of hepatocyte iron loading
[11, 12]. Interestingly, notwithstanding the low hepcidin levels,
and, therefore likely high surface ferroportin expression, in the
HO-1-deficient patient, circulating iron levels are still low and iron
accumulation is still present in the kidneys and the liver, suggest-
ing that the export of cellular iron for the expanded erythopoiesis
demand is still hampered in the patient. This further illustrates the
crucial role of HO-1 to provide enough bioavailable iron for erytho-
pogesis. Further studies however are warranted to unravel mech-
anisms involved during accelerated erythropogesis.
In this manuscript, we have examined the links between HO-1
and the recently found iron regulatory hormone hepcidin and its
target molecule, ferroportin, in order to (i ) delineate the mechanistic
basis of iron regulation and furthermore to (ii ) help explain the
dysregulation of iron homeostasis in HO-1 deficiency. We pro-
vided evidence that HO-1 increases intracellular labile iron levels,
which in monocytic cells induces expression of the iron exporter
ferroportin. We observed very low hepcidin levels in the HO-1-
deficient patient, despite the presence of chronic inflammation and
iron accumulation, both inducers of hepcidin. This condition may
be relevant to many iron-loading anemia disorders, in which ery-
throid regulators together with hypoxic conditions dominantly
suppress synthesis of the iron hormone hepcidin, despite the
presence of stimuli from both inflammatory and iron regulators.
Summarizing, our data suggest that the imbalance of iron metab-
olism in the HO-1-deficient patient is a result of both defective iron
recycling of the reticulo-endothelial-system after erythrophagocy-
tosis, and reduced hepatocyte hepcidin expression secondary to
anemia-induced expansion of erythropoiesis. These findings sup-
port crucial roles of HO-1 and hepcidin in maintaining systemic
iron homeostasis.
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Fig. 5 Proposed pathogenesis of heme oxy-
genase-1 deficiency. The figure illustrates
the reported findings (in boxes) combined
with current knowledge showing a hypothet-
ical sequence of events initiated by HO-1
deficiency leading to severe dysregulation of
iron metabolism. HO-1 deficiency promotes
a substantial decrease in heme catabolism.
This leads to iron-restricted erythropoiesis
and stress-induced hemolysis, and both
result in anemia. The anemia activates the
body machinery of erythropoiesis, leading to
induction of sTfR and suppression of hep-
cidin, necessary to fulfil iron demand for the
accelerated marrow erythropoietic activity.
The erythropoietic drive subsequently low-
ered serum iron and transferrin saturation.
Suppression of hepcidin however promotes
further distortion of iron homeostasis.
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